Pyxis Oncology Appoints Industry Veteran Michael A. Metzger to Board of Directors

Boston-based Pyxis Oncology, Inc. (Nasdaq: PYXS), a company at the forefront of developing new therapeutic strategies for hard-to-treat cancers, has announced a strategic enhancement to its leadership. The appointment of Michael A. Metzger as a member of its Board of Directors signifies a significant move for Pyxis Oncology. With extensive expertise in the biopharmaceutical sector, Metzger brings a wealth of knowledge and experience to the board, further strengthening the company's governance as they continue to progress through the critical stages of clinical development.

Michael A. Metzger's Expertise

Michael A. Metzger has made a notable impact in the industry, recognized for his role in orchestrating successful strategies for growth and development within the pharmaceutical sector. His previous experiences have equipped him with invaluable insights into the intricacies of drug development and commercialization, skills that will be essential as Pyxis Oncology continues to innovate and expand its pipeline of antibody-drug conjugates (ADC) and monoclonal antibodies (mAb).

About Pyxis Oncology

Pyxis Oncology, Inc. (Nasdaq: PYXS) is distinguished by its commitment to addressing the unmet medical needs in oncology. Headquartered in Cambridge, Massachusetts, the preclinical biotechnology firm is concentrating its efforts on pioneering ADC and mAb immunotherapies. These targeted treatments hold the promise of improving outcomes for patients confronting challenging cancer diagnoses. Pyxis Oncology's dedication to research and development is a testament to its mission to change the course of cancer treatment.

Pyxis, Oncology, Appointment